详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia

262| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [a]Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China [b]Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [c]Department of Cadre Health Care, Beijing Jishuitan Hospital, Beijing, China [d]State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

出处：

DOI：

ISSN：

关键词： Ceramide Cognitive impairment Neuropsychiatric symptom Parkinson's disease

摘要：

Background: The abnormal metabolism of ceramides may account for the pathogenesis of Parkinson's disease dementia (PDD). However, the effect of ceramides on cognitive domain impairments and neuropsychiatric symptoms of PDD remains unknown. Methods: A total of 38 PDD, 40 PD with no cognitive impairment (PD-NC) and 40 normal controls were included. A series of cognitive tests and the Neuropsychiatric Inventory (NPI) were used to assess cognitive domains and neuropsychiatric symptoms. A non-fasting blood sample was obtained from each subject Plasma ceramide levels were tested by HPLC-MS/MS analysis. Results: C14:0 and C24:1 levels were significantly higher in PDD than in PD-NC and normal controls. Verbal memory was negatively correlated with C14:0 and C24:1. After controlling for confounding factors, C22:0, C20:0 and C18:0 were significantly associated with hallucinations, anxiety and sleep behavior disturbances, respectively. Conclusion: In PDD, the increase in ceramide levels was correlated with decreased memory function and associated with higher odds of multiple neuropsychiatric symptoms. (C) 2016 Elsevier B.V. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 3 区医学

小类 | 4 区临床神经病学 4 区神经科学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区临床神经病学 3 区神经科学

JCR分区：

出版当年[2014]版：

Q2 CLINICAL NEUROLOGY Q3 NEUROSCIENCES

最新[2023]版：

Q1 CLINICAL NEUROLOGY Q2 NEUROSCIENCES

影响因子： 3.7 最新[2023版] 3.2 最新五年平均 2.474 出版当年[2014版] 2.535 出版当年五年平均 2.262 出版前一年[2013版] 2.126 出版后一年[2015版]

第一作者：

第一作者机构： [a]Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China

共同第一作者：

通讯作者：

通讯机构： [*1]2 Nanwei Road, Beijing 100050, China [*2]45 Changchun Street, Beijing 100053, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia [2]Ceramide and neuropsychiatric symptoms in Parkinson's disease with cognitive impairment [3]Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease [4]Precuneus Dysfunction in Parkinson's Disease With Mild Cognitive Impairment [5]中国人NAD(P)H:醌氧化还原酶基因多态性与帕金森病遗传易感性的关系 [6]Brain activity in Parkinson's disease patients with mild cognitive impairment [7]美多芭对帕金森病患者血小板中五羟色胺含量的影响与抑郁症状 [8]帕金森病轻度认知功能障碍纹状体体积的异常改变 [9]轻度认知功能损害的BOLD-fMRI研究进展 [10]临床异质性的帕金森病认知障碍分析